To our knowledge, this is the first preclinical study investigating the therapeutic potential of the combination of anti-ROR1-CAR-NK cells with IL-21 intratumorally delivered by oncolytic viruses in treating high-risk NB. This evidence concerns the gene ROR1 and neuroblastoma.